References
1. Mousavi sm, Pourfeizi A, Dastgiri S. Childhood Cancer in Iran.Journal of pediatric hematology/oncology. 2010;32:376-382.
2. pakpour haji agha a, yekani nejhad ms, khoshnevisan a, nikobakht m,
mardani a, kamali ardakani s. Health related quality of life associated
factors among patients with brain tumors. journal of ilam
university of medical sciences. 2013;21(3):1-11.
3. Wilne S, Koller K, Collier J, Kennedy C, Grundy R, Walker D. The
diagnosis of brain tumours in children: a guideline to assist healthcare
professionals in the assessment of children who may have a brain tumour.Arch Dis Child. 2010;95(7):534-539.
4. Wilne S, Collier J, Kennedy C, Koller K, Grundy R, Walker D.
Presentation of childhood CNS tumours: a systematic review and
meta-analysis. Lancet Oncol. 2007;8(8):685-695.
5. Gottardo NG, Gajjar A. Chemotherapy for malignant brain tumors of
childhood. J Child Neurol. 2008;23(10):1149-1159.
6. Guerreiro Stucklin AS, Ramaswamy V, Daniels C, Taylor MD. Review of
molecular classification and treatment implications of pediatric brain
tumors. Curr Opin Pediatr. 2018;30(1):3-9.
7. Mehrazin M, Yavari P. Morphological pattern and frequency of
intracranial tumors in children. Child’s Nervous System.2007;23(2):157-162.
8. Wells EM, Packer RJ. Pediatric brain tumors. Continuum (Minneap
Minn). 2015;21(2 Neuro-oncology):373-396.
9. Bondy ML, Scheurer ME, Malmer B, et al. Brain tumor epidemiology:
consensus from the Brain Tumor Epidemiology Consortium. Cancer.2008;113(7 Suppl):1953-1968.
10. Aghayan Golkashani H, Hatami H, Farzan A, et al. Tumors of the
Central Nervous System: An 18-Year Retrospective Review in a Tertiary
Pediatric Referral Center. Iran J Child Neurol. 2015;9(3):24-33.
11. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment
criteria for high-grade gliomas: response assessment in neuro-oncology
working group. J Clin Oncol. 2010;28(11):1963-1972.
12. Pollack IF. Pediatric brain tumors. Seminars in Surgical
Oncology. 1999;16(2):73-90.
13. Echevarría ME, Fangusaro J, Goldman S. Pediatric central nervous
system germ cell tumors: a review. The oncologist.2008;13(6):690-699.
14. Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS. Experience
with irinotecan for the treatment of malignant glioma.Neuro-oncology. 2009;11(1):80-91.
15. Bouffet E, Capra M, Bartels U. Salvage chemotherapy for metastatic
and recurrent ependymoma of childhood. Child’s Nervous System.2009;25(10):1293.
16. Friedman GK, Spiller SE, Harrison DK, Fiveash JB, Reddy AT.
Treatment of children with glioblastoma with conformal radiation,
temozolomide, and bevacizumab as adjuncts to surgical resection.Journal of pediatric hematology/oncology. 2013;35(3):e123-e126.
17. Wagner L, Turpin B, Nagarajan R, Weiss B, Cripe T, Geller J. Pilot
study of vincristine, oral irinotecan, and temozolomide (VOIT regimen)
combined with bevacizumab in pediatric patients with recurrent solid
tumors or brain tumors. Pediatric blood & cancer.2013;60(9):1447-1451.
18. Sun T, Warrington NM, Rubin JB. Why does Jack, and not Jill, break
his crown? Sex disparity in brain tumors. Biology of sex
differences. 2012;3(1):3.
19. Zaky W, Wellner M, Brown RJ, Blüml S, Finlay JL, Dhall G. Treatment
of children with diffuse intrinsic pontine gliomas with
chemoradiotherapy followed by a combination of temozolomide, irinotecan,
and bevacizumab. Pediatric hematology and oncology.2013;30(7):623-632.
20. Hummel TR, Salloum R, Drissi R, et al. A pilot study of
bevacizumab-based therapy in patients with newly diagnosed high-grade
gliomas and diffuse intrinsic pontine gliomas. Journal of
neuro-oncology. 2016;127(1):53-61.
21. Zhang G, Huang S, Wang Z. A meta-analysis of bevacizumab alone and
in combination with irinotecan in the treatment of patients with
recurrent glioblastoma multiforme. Journal of clinical
neuroscience. 2012;19(12):1636-1640.
22. Parekh C, Jubran R, Erdreich-Epstein A, et al. Treatment of children
with recurrent high grade gliomas with a bevacizumab containing regimen.Journal of neuro-oncology. 2011;103(3):673-680.
23. Aguilera D, Mazewski C, Fangusaro J, et al. Response to bevacizumab,
irinotecan, and temozolomide in children with relapsed medulloblastoma:
a multi-institutional experience. Child’s Nervous System.2013;29(4):589-596.
24. Grill J, Geoerger B, Gesner L, et al. Phase II study of irinotecan
in combination with temozolomide (TEMIRI) in children with recurrent or
refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study.Neuro-oncology. 2013;15(9):1236-1243.